Jardiance, a diabetes med from Eli Lilly ($LLY) and Boehringer Ingelheim that locked up FDA approval last Friday, may trail SGLT-2 market entrants Invokana from Johnson & Johnson ($JNJ) and Farxiga from AstraZeneca ($AZN). But without the safety concerns that plague its competitors, that doesn't mean it can't make a splash. Story